VBI Vaccines Announced Interim Data From The Phase 1 Study Of Its Multivalent Pan-coronavirus Vaccine Candidate, VBI-2901, Based On Interim Data, Peak Responses Were Achieved With Only A Single 10µg Dose Of VBI-2901
Author: Benzinga Newsdesk | September 27, 2023 07:34am